History Print

In 1986/87 a new ifa entity was founded for the development and distribution of software specialized in ophthalmology. Within 2 years ifa systems became the market leader for eye care software in Germany.

The international market was approached for the first time in 1992 (AAO in Dallas). Language versions of the complete ifa modules have been developed in English, Spanish, Italian and Flemish, Finnish and Portuguese.

Starting in 1993 ifa software applications have been installed in Austria, Switzerland, Luxemburg, Netherlands, Spain, USA and Canada.

Another milestone was the international EU-sponsored project OPHTEL which started in 1996. The ifa team was the leading software partner and developed the basics for telemedicine in ophthalmology based on the unique data model.

In 2001 the ifa group of companies was restructured with a MBO by its management and team. The company went public in 2005 in Frankfurt, Germany (Entry Standard Stock Market). The management and team hold approx. 76% of the shares (free float 24%). The company is completely independent from banks or investors (without any foreign capital).

In 1996 the new version of the international ifa software has been released combining EMR applications with software for quality management and practice resource planning in ophthalmology.

In 2008 another milestone was reached: ifa systems AG together with its daughter company integration.AG became the exclusive IT provider for the EU-sponsored project EUREQUO (European Registry of Quality Outocomes for Cataract and Refractive Surgery).

In 2009, the ifa team introduced the third software generation with its new template based (SNOMED compatible) user interface. Furthermore, a professional sales and support infrastructure were established for the US market.

In 2010, the ifa team introduced the ifa4iPad version for the Apple iPad. ifa has also attained the ISO certification for internal quality management (DIN EN 9001:2008). Furthermore, ifa systems AG has increased its share ownership in integration.AG to 100%.


In 2011 the international market development project for Health IT in ophthalmology was launched based on a comprehensive research phase worldwide. In the same year the EHR/EMR version for the “Meaningful Use” in the USA was introduced and certified by the ONC (Office of the National Coordinator for Health IT). Parallel a new EMR generation was launched: the bilingual V2020 (version).


In 2012 the first ecPACS application (based on the V2020) was installed at one of the world wide leading eye institutes (RVEEH = Royal Victorian Eye and Ear Hospital in Melbourne, Australia). With the ESCRS in Dublin (European Society for Cataract and Refractive Surgery) a 5-years contract was signed for the international management of the web based quality registry EUREQUO (European Registry for Quality Outcome in Cataract and Refractive Surgery). The INOVEON Corp. in Oklahoma (ifa subsidiary) launched the clinical eROP study (Retinopathy of Premature).

In 2013  the first Chinese Project (PKUPH, Eye Clinic of the Peking University) was launched with the bilingual EMR version in English and Chinese. In the US the new EHR version for the “Meaningful Use” government funding was tested successfully as a modular version for the MU 2014 edition. Parallel the ifa group was recertified based on ISO 9001 (international quality management standard).

In 2014 a new project for Latin America was launched in Mexico City, MX (Conde Eye Institute). The INOVEON Corp. completed the clinical study for a new medical device (RETeval by LKC). In the US the new IMS version (ICD-10, Meaningful Use, SNOMED) was launched by organizing training and work sessions in Boston, New York and Ft. Lauderdale.    

The company plans a growth rate of 20-30% on the international markets and a further concentration on complex IT projects in ophthalmology.